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ABSTRACT 
Author: Gabrielle Lee 
Title: Fatty Acid Synthase Expression Under Obese Conditions in Breast Cancer 
Cells 
 
Supervising Professor: Linda A. deGraffenried, Ph.D. 
Purpose:  In women, breast cancer is the second leading cause of cancer death, 
and one in eight will develop breast cancer during their lifetime (Siegel et al., 
2016). Furthermore, studies have shown that obesity has been associated with 
worse prognosis in some breast cancer patients. These facts led to this study on 
the effects of obesity on the fatty acid synthase (FASN) in breast cancer. FASN 
catalyzes the formation of long-chain fatty acids such as palmitate. Palmitate is 
commonly used as a component of the phospholipid membrane and for energy. 
Other types of cancer have been shown to harness the activity of the FASN in 
order for increased proliferation and energy. This study has two aims: 1) To 
determine if obesity modulates FASN expression in breast cancer cells, and 2) To 
determine the mechanism behind how obesity modulates FASN.  
 
Experimental Design: Sera was obtained from women and pooled by Body Mass 
Index (Normal weight: 18.5 – 24.9 kg/m2, Obese: ≥ 30 kg/m2). MCF-7 cells, an 
estrogen receptor and progesterone receptor positive breast cancer cell line, was 
grown in 2% obese or 2% normal women sera to model cell growth in vivo. The 
effect of obese and normal women sera on FASN expression was measured 
through quantitative PCR. 
 
Afterwards, MCF-7 cells were grown in normal growth media or normal growth 
media with 0.5 mM of H2O2 in order to see the effects of hypoxia on cell 
expression of FASN. Again, FASN expression was measured through quantitative 
qPCR. 
 
Results: Treatment with 2% obese women sera on MCF-7 cells increased FASN 
expression by approximately 2.5-fold. Hypoxic conditions on MCF-7 cells 
increased FASN expression by approximately 4-fold. The effect of obesity on 
FASN in breast cancer cells is still being investigated. 
 
Conclusions: Exposure to sera from obese women increases the presence of FASN 
for energy and for membrane formation in breast cancer cells. Furthermore, cells 
produce various factors that increase FASN expression under hypoxic conditions. 				
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INTRODUCTION 
 
 Cancer plagues our country as the second leading cause of death, and 
experts have estimated that there will be almost 250,000 new cases of breast 
cancer this year alone (Siegel et al., 2016). Additionally, more and more 
Americans are gaining weight and becoming obese every year. When looking at 
the relationship between breast cancer and obesity, studies showed that obesity 
has been associated with a worse prognosis in breast cancer patients, and obesity 
is considered an established risk factor for the development of postmenopausal 
breast cancer (Sinicrope and Dannenberg, 2011). This is partially explained 
because obesity induces changes in cellular metabolism and causes hypoxic 
conditions. Since hypoxic conditions lead to rapid proliferation in cancer cells 
partially through increased expression of the fatty acid synthase (FASN), it is 
hypothesized that obesity increases expression of FASN. Overexpression of FASN 
has been shown in different types of cancer including breast, prostate, and 
ovarian (Flavin et al., 2010). Furthermore, FASN plays an integral part in tumor 
development and progression (Duan et al., 2016). The expression of FASN and its 
significance in breast cancer remains vague and led to this study. Obese breast 
cancer patients are more likely to experience resistance to treatment. Defining 
the role and mechanism FASN has in obese breast cancer patients would be 
integral in determining whether FASN is a target to go after for cancer treatment. 
The fatty acid synthase is a multi-enzyme complex composed of two 
identical monomers. Each monomer contains six catalytic activities necessary for 
	 6	
function. However, fatty acid synthase functions only in dimer form (Chirala and 
Wakil, 2004). 
 
Figure 1: The primary role of FASN is to catalyze the synthesis of 
palmitate from free fatty acids. Palmitate is a long chain fatty acid that could go 
through two processes in the cell. On one hand, palmitate can be used to form 
phospholipids necessary for membrane formation and ultimately, proliferation. 
On the other hand, palmitate can go into the mitochondria, and through beta-
oxidation, the TCA cycle, and the electron transport chain, produce ATP for 
energy processes (DeBardinis et al., 2008).  
 
Cancer cells utilize FASN to form the phospholipid membrane needed 
during cell division and to derive energy. Since cancer cells are rapidly 
proliferating, they require more energy. Normal cells do not express high levels of 
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FASN unless during cell division. The use of FASN to produce the fatty acids 
required for energy and proliferation allows cancer cells to rapidly divide.  
 Obesity associated hypoxic conditions are induced in a variety of ways. For 
instance, expanding adipose tissue, due to obesity, disrupts capillary function and 
creates hypoxic microenvironments (Ye, 2012).  
 
Hypothesized Mechanism by which Obesity Upregulates FASN 
  
Figure 2: Obesity induces hypoxic environments. Hypoxia significantly 
increases phosphorylation of Akt and activation of hypoxia-inducible factor 1 
(HIF1). This leads to upregulation of sterol regulatory-element binding protein 
(SREBP-1). SREBP-1 is a transcription factor that binds to the SREBP binding 
site/E-box sequence located in the FASN promoter. Under hypoxic conditions, 
SREBP-1 binds more strongly to this area. SREBP-1 binding to the FASN 
promoter results in increased expression of FASN. Therefore, hypoxia ultimately 
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upregulates the gene expression of FASN through the HIF1/Akt pathway (Furuta 
et al., 2008). Cancer cells harness FASN and go through the processes for both 
proliferation and energy. Therefore, it is hypothesized that obesity affects FASN 
expression by inducing hypoxic conditions in the tumor microenvironment, and 
increased levels of free fatty acids in obese patients contribute to production of 
palmitate. 
 
Hypothesis: Obesity induces hypoxic conditions, which ultimately 
upregulates FASN 
 For this project, specific aims were developed in order to explore the 
relationship between obesity and breast cancer. 
Specific Aim 1a – Determine if exposure to obese conditions induces 
upregulation of FASN expression levels in breast cancer cells  
Obesity promotes cancer progression, but the specific mechanisms by 
which this occurs are unclear. FASN has been shown to promote cancer cell 
proliferation and malignant progression through generating fatty acid precursors 
required for cell proliferation, altering membrane fluidity and activating 
oncogenic signaling pathways. Therefore, it is possible that circulating factors in 
sera from obese individuals might lead to increased expression of FASN in cancer 
cells. 
Specific Aim 1b – Determine the mechanism by which obesity 
modulates FASN expression in breast cancer cells 
 Obesity is associated with elevated levels of numerous circulating growth 
factors, adipokines, and inflammatory cytokines that can activate the Akt 
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signaling pathways. It is hypothesized that obesity associated hypoxic conditions 
increase the presence of these factors, and they are present in sera obtained from 
obese women. Therefore, it is hypothesized that subjecting the cells to hypoxic 
conditions, or subjecting them to the circulating factors contained in this sera, 
will activate the HIF1/Akt signaling pathway and increase expression of FASN. 
 
Discovering the answers to these questions would be useful in clinical 
settings. Therefore, this translational research laboratory started collaborating 
with the University of Texas Health Science Center at San Antonio for this 
project. The results of this project will lead to future experiments regarding a 
specific fatty acid synthase inhibitor, TVB-3166, currently in a Phase 1 clinical 
drug trial for treating glioblastomas. This particular inhibitor was chosen because 
it presents with fewer side effects in patients with glioblastomas. The use of other 
fatty acid synthase inhibitors in breast cancer patients has resulted in 
unintended, dramatic weight loss. Therefore, it is hypothesized that TVB-3166 
could be a better potential treatment for obese breast cancer patients, who are 
particularly prone to obesity related cancer therapy resistance due to the factors 
produced in obese conditions. 
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MATERIAL AND METHODS 
 
Cell Lines  
MCF-7 (ER/PR +), a human breast carcinoma cell line, was maintained in IMEM 
supplemented with 10% fetal bovine serum, 5% penicillin/streptomycin, and 0.01 
mg/ml human recombinant insulin. The cell line was subjected to four 
conditions: normal growth media (10% FBS), normal growth media with 
hydrogen peroxide (10% FBS + 0.5 mM H2O2), 2% obese donor sera (SFM+ 2% 
obese donor sera), and 2% normal donor sera (SFM + 2% normal donor sera). 
Human sera were obtained from normal weight and obese postmenopausal 
women from Equitech Enterprises. The collected sera were pooled into two 
groups by Body Mass Index (Normal weight: 18.5 – 24.9 kg/m2, Obese: ≥ 30 
kg/m2). 
 
RNA Extraction 
Total RNA was isolated from the cells with TRIzol® Reagent (Life Technologies, 
2012). 
 
Reverse Transcription  
cDNA was reverse transcribed from previously extracted RNA using the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 2006). 
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qPCR 
FASN mRNA expression was measured through quantitative Polymerase Chain 
Reaction and quantified by SYBR green dye binding. The cDNA was amplified 
with a pair of forward and reverse primers for the following genes: FAS (5′-
CATCCAGATAGGCCTCATAGAC-3′ and 5′-CTCCATGAAGTAGGAGTGGAAG-3′) 
and β-actin (5′-TGAGACCTTCAACACCCCAGCCATG-3′ and 5′-
CGTAGATGGGCACAGTGTGGGTG-3′). qPCR reactions were performed using 
SYBR® Select Master Mix (Life Technologies, 2013). The qPCR gene expression 
was normalized to human β-actin. All experiments were executed in triplicates 
and will be repeated three independent times. 
 
Statistical analysis 
Results were expressed as the mean±SEM. Statistical tests included paired, one-
tailed Student test. P-values of 0.05 or less were considered to denote 
significance. 
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RESULTS 
 
The MCF-7 cell line was utilized for this experiment. MCF-7 human breast 
cancer cell line was derived from a pleural effusion from a patient with metastatic 
breast cancer (Levenson and Jordan, 1997). MCF-7 has estrogen receptors and 
progesterone receptors, and can be classified as Luminal A breast cancer in 
clinical terms. Luminal A breast cancer is the most common subtype of breast 
cancer. Luminal A represents 50-60% of all breast cancers, so performing these 
studies with the MCF-7 breast cancer cell line would be the most relevant to the 
clinical setting (Yersal and Baructa, 2014). The traditional way of executing these 
experiments are through a monolayer two-dimensional culture, therefore this 
method was implemented.  
The first step to fulfill Specific Aim 1a was to see if cells treated with sera 
from obese women would increase or decrease the expression of FASN (Figure 3). 
The various factors that are elevated in obese conditions could be activating the 
HIF1/Akt pathway that leads to upregulation of FASN. The results showed an 
approximately 2.5-fold increase in FASN mRNA levels in cells treated with obese 
donor sera for 24 hours. The data suggests that obesity causes cells to secrete 
various factors that will be present when sera from obese women is collected. 
This experiment was done three times, and the results are statistically significant 
at a 5% confidence level with a P-value of 0.03. 
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Figure 3: Quantitative PCR was used to measure the FASN mRNA levels in 
MCF-7 breast cancer cells after a 24 hour exposure to 2% sera from normal 
weight (BMI = 18.5 – 24.9 kg/m2) or obese (BMI ≥ 30 kg/m2) postmenopausal 
women. There is approximately a 2.5-fold increase in FASN mRNA levels when 
cells are exposed to sera from obese women. (P-value = 0.03) 
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Treating cells with hydrogen peroxide was the next step to fulfill Specific 
Aim 1b in order to elucidate the mechanism by which obesity is inducing 
increased FASN expression. It was hypothesized that hypoxic conditions caused 
by obesity would stress the cell into inducing the production of various factors 
involved in the HIF1/Akt pathway. Since obesity induces hypoxia, using hydrogen 
peroxide is a good model for the hypoxic environment induced by obesity without 
the circulating factors to see if the cell will still induce expression of FASN 
(Furuta et al., 2008).  
The results from this experiment (Figure 4) showed that cells treated with 
0.5 mM of hydrogen peroxide in normal growth media for 24 hours had a 4-fold 
increase in FASN mRNA expression levels. When cells were treated with 
hydrogen peroxide, they would become stressed and produce factors that would 
contribute to increased FASN mRNA expression. Cells treated in normal growth 
media would not be stressed, and would use the nutrients in the media for growth 
and energy purposes instead of FASN. The results suggests that inherent factors 
produced when the cells are stressed also upregulate FASN expression levels. 
Therefore, the data proposes that circulating factors as well as inherent factors 
induce expression of FASN. This experiment was carried out once, and further 
experiments are currently in progress. 
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Inherent Factors Increase FASN Expression Under Hypoxia 
 
Figure 4: Quantitative PCR was used to measure the FASN mRNA levels in 
MCF-7 breast cancer cells after a 24 hour exposure to 10% FBS or 10% FBS + o.5 
mM H2O2. There is an approximately 4-fold increase in FASN mRNA levels when 
cells are exposed to hydrogen peroxide. This experiment is in the process of being 
replicated, so statistics cannot be performed at this point. 													
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Troubleshooting by mixing and matching different doses of hydrogen 
peroxide with different time points was a long process. Doses of 0 mM, 0.5 mM, 
and 1 mM of hydrogen peroxide were used, and 24 and 48 hour time points were 
tested. Furthermore, serum starving the cells overnight before treating them for 
24 or 48 hours was tested as well. Serum starving was quickly ruled out as 
unnecessary because the cells needed to be at their baseline before measuring 
FASN expression levels. Starving the cells before adding the treatment would 
skew results since serum starving itself could affect FASN expression levels. 
Treating for 24 hours would yield results, while treating for 48 hours would kill 
the cells. Finally, treating the cells with 1 mM of hydrogen peroxide would also 
kill the cells. Using a 0.5 mM dose of hydrogen peroxide was also confirmed 
through other published works (Furuta et al., 2008). 
One of the major obstacles in this experiment was obtaining 
uncontaminated RNA. RNA extraction was a difficult process that needed 
troubleshooting. Using the TRIzol® Reagent protocol (Life Technologies, 2012), 
under homogenizing samples, on the third step of the adherent cells (monolayer) 
section, it was best to use cell scrapers to aid the lysing and homogenizing 
process in addition to pipetting up and down the solution. In the second step of 
phase separation, it was found that chloroform is prone to evaporation. 
Therefore, wetting the pipet tip before loading chloroform into the tip would give 
the accurate amount of chloroform needed. Completely removing as much liquid 
as possible in step 4 of RNA wash was crucial in giving clean, uncontaminated 
RNA. Removing the last drops of liquid could be achieved by collecting the liquid 
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at the bottom of the tube through centrifuging. These extra additions would yield 
higher quality RNA. Higher quality RNA would yield a qPCR reaction with more 
reliable results. High quality RNA could be determined through Nanodrop. High 
quality RNA would have a 260/280 absorbance value close to 2.0, and a 260/230 
absorbance value ranging from 2.0-2.2. Since RNA is extremely unstable and 
prone to degradation, it was discovered that running a Reverse Transcriptase 
PCR (RT-PCR) right after extracting RNA from the cells, instead of freezing it 
back for storage and then thawing to continue the experiment, would give quality 
cDNA. 
 cDNA obtained from (RT-PCR) is stable, but it was discovered that mixing 
cDNA through vortexing would break the cDNA strands. The optimal way to mix 
cDNA was to gently flick the tube. 
According to the SYBR® Select Master Mix protocol, the optimal primer 
concentration range is 150 nM – 400 nM (Life Technologies, 2013). After testing 
300 nM, 350 nM, and 400 nM of FASN primers in the qPCR reaction, we 
established that a 400 nM FASN primer reaction was the most efficient. The 
qPCR ran more effectively and yielded the most reliable results at this primer 
concentration. Precise pipetting was achieved by using master mixes containing 
primer, cDNA and SYBR® Select Master Mix. The standard cycling mode was 
used for qPCR, and it gave the most reliable results (Life Technologies, 2013). 						
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DISCUSSION 
 
Cells treated with sera from obese women showed an almost 2.5-fold 
increase in FASN mRNA expression levels. This result was statistically significant 
and suggests that factors in the sera from obese women induce increased FASN 
mRNA levels, and obesity affects the expression of FASN, which promotes cancer 
progression. Since obesity is associated with elevated levels of numerous 
circulating growth factors, adipokines, and inflammatory cytokines that can 
activate the Akt signaling pathways, we hypothesize that these increased levels of 
different factors will activate the HIF1/Akt signaling pathway which increases 
expression of FASN (Bowers, 2014). Furthermore, cells themselves are affected 
by hypoxic conditions and will produce factors that increase expression of FASN. 
Factors secreted by cells in combination with factors produced by the cell itself 
will promote expression of FASN and ultimately drives cancer progression. 
 A future step this study could take is to investigate if the HIF1/Akt 
pathway is truly being upregulated. This would be accomplished by treating the 
cells with obese and control sera and using a Western Blot with an antibody for 
Akt.  
The specific microenvironment of the breast also has many factors that 
contribute to the survival and progression of breast cancer. Since the breast is 
made up of adipose tissue, pre-adipocytes are the next target to look at. Another 
step this project could go in is to measure FASN mRNA expression levels in pre-
adipocytes after being treated with sera from either obese or non-obese women. 
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Pre-adipocytes are the undifferentiated form of adipocytes. They are pro-
inflammatory and more bioactive than adipocytes, making them an attractive 
target for the next step. The results from this will show whether FASN mRNA 
levels are increased in pre-adipocytes treated with sera from obese women or not. 
Ultimately, it is hypothesized that palmitate from FASN in pre-adipocytes can be 
secreted out of the pre-adipocyte. Cancer cells can then use the exogenous free 
fatty acids as an additional source of palmitate for proliferation and/or energy 
(Louie et al., 2008). 
Since it has been shown that obesity confers increased resistance in 
different types of therapies for breast cancer (Hursting et al., 2015), the last step 
of this project would be to test a fatty acid inhibitor (TVB-3166), currently in a 
phase 1 clinical drug trial for glioblastoma, on breast cancer cells. The results 
from this would show if this fatty acid inhibitor would be an effective treatment 
for obese breast cancer patients. This fatty acid inhibitor could potentially be a 
more beneficial treatment specifically for obese breast cancer patients.  
 
Further aims currently planned out for this project to explore after Specific 
Aim 1a and 1b are completed are listed as follows: 
Specific Aim 2 – Determine if exposure to obese conditions 
upregulate FASN expression in pre-adipocytes 
In addition to altered expression in epithelial cells, FASN levels in 
adipocytes have been shown to be altered in the obese individual, potentially 
contributing to increased circulating levels of free fatty acids that can fuel cancer 
cell growth and proliferation. Replicating the qPCR studies in Specific Aim 1 
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using human pre-adipocytes would determine if exposure to sera from obese 
women upregulates expression of FASN in the pre-adipocytes. 
This experiment will determine if obesity induces release of free fatty acids 
from the pre-adipocytes. Next would be to generate conditioned media from pre-
adipocytes exposed to sera from either obese or lean women for 24 hours and 
measure the free fatty acid content using Abcam’s Free Fatty Acid Quantification 
Kit. The pre-adipocytes would briefly be exposed to the same conditions as in 
Specific Aim 1a: 2% obese donor sera (SFM+ 2% obese donor sera) and 2% 
normal donor sera (SFM + 2% normal donor sera).  After 24 hours, media would 
be removed, cells would be washed with PBS, and fresh SFM would be added to 
the cells.  This conditioned media would then be collected after 24 hours, and the 
free fatty acid content would be measured. This experiment is currently in 
progress. 
 
Specific Aim 3 – Determine if use of a FASN inhibitor suppresses 
obesity-induced proliferation in vitro 
Previous studies using less specific FASN inhibitors have demonstrated 
that FASN is a viable target for therapeutic intervention in other cancer cell types.  
These early inhibitors also induced significant weight loss, limiting use for the 
cancer patient.  Newer, more targeted and reversible FASN inhibitors such as 
TVB-3166 have not demonstrated similar weight loss complications in early 
clinical studies, suggesting that these newer compounds may provide a highly 
effective, less toxic alternative for the treatment of certain breast cancers 
(Ventura et al., 2015).  It is hypothesized that since obesity promotes worse 
	 21	
outcome in all breast cancer tumor types, and in both menopausal and 
postmenopausal women, TVB-3166 may be effective at suppressing disease 
progression in several clinical subtypes. Future steps this project would take 
would be to use in vitro modeling to assess the efficacy of TVB-3166 at limiting 
obesity-induced parameters of progression.  Concentrations of TVB-3166 (50 
nM) are based upon previous studies done by 3-V Biosciences (Ventura et al., 
2015). This experiment is also currently in progress. 
These pending experiments will determine the role of FASN in breast 
cancer cells and if TVB-3166 is effective at limiting obesity-induced changes in 
cellular behavior associated with progression. MTT and Ki67 assays could be 
used to determine changes in proliferation, and wound healing assays could be 
used to determine changes in motility, and invasion chambers to determine 
changes in invasive potential. 
Currently, MTT assays are being utilized to measure cell viability of cells 
treated with different doses of TVB-3166 in 2% FBS, 2% obese donor sera, and 
2% normal donor sera. 
 The last direction this project could go in is to repeat these experiments in 
other breast cancer cell line subtypes. This would show if there is a difference in 
how obesity impacts other types of breast cancer, and if so, how TVB-3166 
efficacy would be affected.  
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CONCLUSIONS 
 
This project has shown that obesity upregulates FASN. This is potentially 
due to a combination of obesity-associated hypoxic conditions and increased 
levels of circulating factors. Further research is necessary to conclude if these 
results are specific to this particular cell type, if other cells in the tumor 
microenvironment have the same effects on breast cancer, and if FASN inhibitors 
could potentially reduce cancer cell proliferation and improve breast cancer 
prognosis.
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